Christopher Sears
Dr. Christopher Sears, Chief Scientific Officer at Ambergen, has worked extensively in the field of molecular diagnostics. In his previous position as Director of Clinical Genomics at the Dana Faber Cancer Center, he supervised a team of scientists involved in technology development for mutation analysis and cancer marker discovery. He has also contributed significantly to the development of several highly successful commercial screening assays and oversaw the development of national clinical trial informatics projects. Dr. Sears has an extensive bioinformatics background including biostatistical analysis of high-dimensional data to extract signatures of diagnostic value. He received his Doctorate in Biochemistry and Molecular and Cellular Biology from Harvard University. Dr. Sears has held academic appointments at Harvard University and Medical School, and more recently at the Broad Institute and Children's Hospital Boston. He is retained as a subject matter expert in genomics by the U.S. Government Department of Justice, and serves on advisory boards of several biotechnology companies.
Z. James Han
Dr. Z. James Han is Director of New Assay Technology at Ambergen. He has over 20 years experience in molecular biology, applied genomics and cancer assay development including the development of assays for CRC. In his previous position as Principal Scientist at Exact Science Corporation, he helped develop PreGen-Plus V2 and ColoSure, non-invasive CRC assays offered by LabCorp (Laboratory Corporation of America). Dr. Han received his Ph.D. from Boston College, Department of Biology and his Ph.D. thesis, “Analysis of Schizosaccharomyces pombe mitochondrial DNA replication by two dimensional gel electrophoresis”, won the Chromosoma Prize 1995 for the best paper in Chromosoma published during 1994. His postdoctoral training was at Harvard Medical School, focusing on the mechanisms of stationary phase of the bacterial life cycle.
Mark Lim
Dr. Mark Lim is Director of Proteomics at Ambergen. He received his Ph.D. in Vascular Cell Biology and Proteomics in 2000 from Boston University and has extensive experience in the fields of proteomics, protein biochemistry, cell biology, physiology as well as immunoassays and assay development. At Ambergen, he has spear-headed the development of several proprietary cell-free protein expression based technologies, including a high throughput ELISA-based diagnostic assay for the detection of chain truncating mutations associated with inherited forms of colorectal cancer (Gite et al., Nature Biotechnology, 2003). He has also pioneered the development of Ambergen’s proprietary proteomics technologies including cell-free expressed proteome libraries as well as photocleavage based protein array printing and protein isolation, the foundation for which was recently published in Analytical Biochemistry (Lim and Rothschild, 2008).
Kenneth J. Rothschild
Dr. Rothschild is Chairman of the Board and Co-founder of Ambergen. He has been an innovator in biotechnology for the past 35 years, contributing to the fields of membrane protein biophysics, vibrational spectroscopy, nanotechnology and molecular diagnostics. Dr. Rothschild holds over 35 issued U.S. patents and is the author of over 150 publications in major scientific journals. Distinctions include General Motors Scholar, Fellow of the Sloan Foundation, Fellow of National Research Council, Established Investigator of the American Heart Association, Fellow of the American Physical Society and Fellow of the Biophysical Society. Dr. Rothschild is a Professor of Physics at Boston University and Associate Professor of Biophysics and Physiology at the Boston University School of Medicine. He also holds faculty appointments at the Center for Photonics, Polymer Center and Center for Bioinformatics at Boston University. Dr. Rothschild received his Ph.D. in Physics at the Massachusetts Institute of Technology and was a Research Associate in the Harvard-MIT Program in Health Sciences and Technology.
